Exclusive Summary

• Teatvir+Ritonavir, as a novel innovative combination drug, benefits from patent protection, offering a unique market entry point for unmet viral disease needs.
• The product targets a large patient population with significant unmet medical needs in its disease area, supporting global market expansion.
• This innovative drug is expected to offer differentiated clinical advantages in efficacy, safety, or compliance over existing standard treatments, potentially leading to treatment guideline recommendations.
• With international certifications, robust registration experience, and competitive pricing, it presents an excellent commercial opportunity for global BD cooperation, leveraging its innovative status to avoid generic competition during patent protection.
• During its original patent exclusivity, as an innovative drug, it can bypass generic competition and rapidly enter target markets through Distribution models.